News on pharmacovigilance
20 January 2020
-
PRAC assesses that NAION could be a very rare side effect of Ozempic, Rybelsus and Wegovy
| 19 March 2026 |
EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) recommends that the product information for semaglutide medicines should include information that the rare eye condition NAION could be a very rare side effect. Treatment should be stopped if symptoms of NAION occur.